Últimas noticias sobre Central Puerto (NYSE:CEPU) Bolsa

Central Puerto

Central Puerto SA is a private-sector power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity.. The company derives maximum revenue from Electric Power Generation from conventional sources segment.

CEPU

Descubre por qué los brokers argentinos prefieren el sector energético, a pesar de la reciente volatilidad del mercado de renta variable.

Acciones argentinas: brokers apuestan por el sector energético pese a la volatilidad

Central Puerto S.A. American Depositary Shares (each represents ten Common Shares)

Central Puerto SA

Byrna Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYRN#NASDAQ">BYRN</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-04-10. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Byrna Technologies will report an earnings per share (EPS) of $0.01.
The market awaits Byrna Technologies's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.16, leading to a 0.0% drop in the share price on the subsequent day.
Here's a look at Byrna Technologies's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.05</td>
<td>0.05</td>
<td>0.03</td>
<td>-0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.21</td>
<td>0.08</td>
<td>0.12</td>
<td>0</td>
</tr>
<tr>
<td>Price Change %</td>
<td>8.0%</td>
<td>-3.0%</td>
<td>-7.000000000000001%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1744207302_0.png" alt="eps graph" />
<h3>Byrna Technologies Share Price Analysis</h3>
Shares of Byrna Technologies were trading at $15.07 as of April 08. Over the last 52-week period, shares are up 2.15%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/BYRN/earnings">To track all earnings releases for Byrna Technologies visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

BYRN

A Look at Byrna Technologies's Upcoming Earnings Report

Keybanc analyst Justin Patterson maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Overweight and lowers the price target from $675 to $625.

News

Price Target

Analyst Ratings

SPOT

Keybanc Maintains Overweight on Spotify Technology, Lowers Price Target to $625

Jefferies analyst Stephanie Moore maintains Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) with a Hold and lowers the price target from $255 to $230.

Jefferies Maintains Hold on Union Pacific, Lowers Price Target to $230

Bank7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSVN#NASDAQ">BSVN</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-04-10. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Bank7 will report an earnings per share (EPS) of $0.95.
Anticipation surrounds Bank7's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
The company's EPS beat by $0.11 in the last quarter, leading to a 0.22% drop in the share price on the following day.
Here's a look at Bank7's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.05</td>
<td>1.07</td>
<td>1.04</td>
<td>1.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.16</td>
<td>1.24</td>
<td>1.23</td>
<td>1.21</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>7.000000000000001%</td>
<td>5.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1744207288_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Bank7 were trading at $35.79 as of April 08. Over the last 52-week period, shares are up 31.92%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/BSVN/earnings">To track all earnings releases for Bank7 visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSVN

A Glimpse of Bank7's Earnings Potential

In the last three months, 13 analysts have published ratings on Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $65.38, along with a high estimate of $72.00 and a low estimate of $48.00. This current average reflects an increase of 1.05% from the previous average price target of $64.70. 
<img src="https://www.benzinga.com/files/images/story/2025/1744207282_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Avidity Biosciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Joseph Stringer &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $60.00&#x7C;$60.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $72.00&#x7C;$72.00 &#x7C; 
&#x7C;Joseph Stringer &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $60.00&#x7C;$60.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $72.00&#x7C;$72.00 &#x7C; 
&#x7C;Keay Nakae &#x7C;Chardan Capital &#x7C;Maintains &#x7C;Buy &#x7C; $65.00&#x7C;$65.00 &#x7C; 
&#x7C;Geoff Meacham &#x7C;Citigroup &#x7C;Announces &#x7C;Buy &#x7C; $70.00&#x7C;- &#x7C; 
&#x7C;Kostas Biliouris &#x7C;BMO Capital &#x7C;Announces &#x7C;Outperform &#x7C; $72.00&#x7C;- &#x7C; 
&#x7C;Geoff Meacham &#x7C;B of A Securities &#x7C;Lowers &#x7C;Buy &#x7C; $48.00&#x7C;$51.00 &#x7C; 
&#x7C;Louise Chen &#x7C;Scotiabank &#x7C;Announces &#x7C;Sector Outperform&#x7C; $70.00&#x7C;- &#x7C; 
&#x7C;Gena Wang &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $57.00&#x7C;$63.00 &#x7C; 
&#x7C;Keay Nakae &#x7C;Chardan Capital &#x7C;Maintains &#x7C;Buy &#x7C; $65.00&#x7C;$65.00 &#x7C; 
&#x7C;Luca Issi &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $67.00&#x7C;$67.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $72.00&#x7C;$72.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Avidity Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Avidity Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Avidity Biosciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Avidity Biosciences's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RNA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Avidity Biosciences analyst ratings.</a>
<h2>Unveiling the Story Behind Avidity Biosciences</h2>
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
<h3>Financial Insights: Avidity Biosciences</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Avidity Biosciences showcased positive performance, achieving a revenue growth rate of 35.57% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Avidity Biosciences's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -3439.52%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Avidity Biosciences's ROE stands out, surpassing industry averages. With an impressive ROE of -6.98%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Avidity Biosciences's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -6.38%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Avidity Biosciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.0.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences Stock

Northern Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTIC#NASDAQ">NTIC</a>) is preparing to release its quarterly earnings on Thursday, 2025-04-10. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Northern Technologies to report an earnings per share (EPS) of $0.06.
The announcement from Northern Technologies is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.05, leading to a 0.0% drop in the share price on the subsequent day.
Here's a look at Northern Technologies's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.12</td>
<td>0.19</td>
<td>0.24</td>
<td>0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.07</td>
<td>0.20</td>
<td>0.11</td>
<td>0.18</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>-1.0%</td>
<td>-7.000000000000001%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1744207276_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Northern Technologies were trading at $9.25 as of April 08. Over the last 52-week period, shares are down 32.73%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/NTIC/earnings">To track all earnings releases for Northern Technologies visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NTIC

Insights into Northern Technologies's Upcoming Earnings

In the last three months, 4 analysts have published ratings on Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Fortrea Holdings and provided 12-month price targets. The average target is $12.0, accompanied by a high estimate of $15.00 and a low estimate of $10.00. Experiencing a 39.24% decline, the current average is now lower than the previous average price target of $19.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1744207270_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Fortrea Holdings by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ann Hynes &#x7C;Mizuho &#x7C;Lowers &#x7C;Neutral &#x7C; $10.00&#x7C;$12.00 &#x7C; 
&#x7C;Elizabeth Anderson &#x7C;Evercore ISI Group &#x7C;Lowers &#x7C;In-Line &#x7C; $15.00&#x7C;$20.00 &#x7C; 
&#x7C;Matthew Sykes &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $11.00&#x7C;$22.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $12.00&#x7C;$25.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Fortrea Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Fortrea Holdings compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Fortrea Holdings's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Fortrea Holdings's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FTRE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Fortrea Holdings analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Fortrea Holdings</h2>
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
<h3>Financial Insights: Fortrea Holdings</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Challenges: Fortrea Holdings's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -1.79%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -8.78%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Fortrea Holdings's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -4.26%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Fortrea Holdings's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.69% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Fortrea Holdings's debt-to-equity ratio is below the industry average at 0.88, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FTRE

Demystifying Fortrea Holdings: Insights From 4 Analyst Reviews

Morgan Stanley analyst Terence Flynn maintains Organon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>) with a Equal-Weight and lowers the price target from $16 to $15.

Morgan Stanley Maintains Equal-Weight on Organon, Lowers Price Target to $15

CureVac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) is set to give its latest quarterly earnings report on Thursday, 2025-04-10. Here's what investors need to know before the announcement.
Analysts estimate that CureVac will report an earnings per share (EPS) of $-0.09. 
Investors in CureVac are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.84, which was followed by a 4.51% drop in the share price the next day.
Here's a look at CureVac's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.60</td>
<td>-0.29</td>
<td>-0.26</td>
<td>-0.20</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.24</td>
<td>-0.32</td>
<td>-0.33</td>
<td>-0.41</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>-0.0%</td>
<td>-7.000000000000001%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1744207265_0.png" alt="eps graph" />
<h3>Market Performance of CureVac's Stock</h3>
Shares of CureVac were trading at $2.72 as of April 08. Over the last 52-week period, shares are down 6.93%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/CVAC/earnings">To track all earnings releases for CureVac visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CVAC

Insights Ahead: CureVac's Quarterly Earnings

WIIM

PACB

Pacific Biosciences of California shares are trading higher after the company reported its Q1 prelimary revenue results.

Across the recent three months, 4 analysts have shared their insights on Genmab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMAB#NASDAQ">GMAB</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $39.75, a high estimate of $50.00, and a low estimate of $27.00. This current average represents a 20.5% decrease from the previous average price target of $50.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1744207256_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Genmab among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Raghuram Selvaraju &#x7C;HC Wainwright &amp; Co. &#x7C;Lowers &#x7C;Buy &#x7C; $37.00&#x7C;$50.00 &#x7C; 
&#x7C;Asthika Goonewardene&#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $45.00&#x7C;$50.00 &#x7C; 
&#x7C;Jonathan Chang &#x7C;Leerink Partners &#x7C;Announces &#x7C;Outperform &#x7C; $27.00&#x7C;- &#x7C; 
&#x7C;Raghuram Selvaraju &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $50.00&#x7C;$50.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Genmab. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Genmab compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Genmab's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Genmab's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GMAB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Genmab analyst ratings.</a>
<h2>Delving into Genmab's Background</h2>
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson &amp; Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson &amp; Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
<h3>Genmab: A Financial Overview</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Genmab's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 35.34%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 59.7%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 11.21%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Genmab's ROA stands out, surpassing industry averages. With an impressive ROA of 9.0%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.03.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GMAB

What Analysts Are Saying About Genmab Stock

Lovesac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#NASDAQ">LOVE</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-04-10. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Lovesac will report an earnings per share (EPS) of $1.85.
The market awaits Lovesac's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Historical Earnings Performance</h3>
Last quarter the company missed EPS by $0.04, which was followed by a 2.33% increase in the share price the next day.
Here's a look at Lovesac's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.28</td>
<td>-0.44</td>
<td>-0.96</td>
<td>1.92</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.32</td>
<td>-0.38</td>
<td>-0.83</td>
<td>1.87</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>3.0%</td>
<td>-8.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1744207255_0.png" alt="eps graph" />
<h3>Market Performance of Lovesac's Stock</h3>
Shares of Lovesac were trading at $12.47 as of April 08. Over the last 52-week period, shares are down 40.76%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analysts' Perspectives on Lovesac</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Lovesac.
With 1 analyst ratings, Lovesac has a consensus rating of Buy. The average one-year price target is $35.0, indicating a potential 180.67% upside.
<h3>Peer Ratings Overview</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of and Purple Innovation, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Purple Innovation, with an average 1-year price target of $1.0, suggesting a potential 91.98% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
The peer analysis summary provides a snapshot of key metrics for and Purple Innovation, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lovesac</td>
<td>Buy</td>
<td>-2.68%</td>
<td>$87.64M</td>
<td>-2.47%</td>
</tr>
<tr>
<td>Purple Innovation</td>
<td>Neutral</td>
<td>-11.62%</td>
<td>$55.28M</td>
<td>-35.21%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Lovesac is positioned better than its peer in terms of Revenue Growth and Gross Profit. However, its Return on Equity is lower compared to the peer. Overall, Lovesac is performing relatively well compared to its peer in the analysis.
<h3>Discovering Lovesac: A Closer Look</h3>
The Lovesac Co designs, manufactures and sells alternative furniture which is comprised of modular couches called sactionals and premium foam beanbag chairs called sacs. It also offers other accessories such as sactional-specific drink holders, Footsac blankets, decorative pillows, fitted seat tables, and ottomans. Its products are sold across the United States through its website or company-owned retail stores which are used in homes and offices. The majority of the firm's revenue is derived from the sale of Sactionals.
<h3>Breaking Down Lovesac's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Lovesac's revenue growth over 3 months faced difficulties. As of 31 October, 2024, the company experienced a decline of approximately -2.68%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Lovesac's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -3.29%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Lovesac's ROE stands out, surpassing industry averages. With an impressive ROE of -2.47%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Lovesac's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -1.01%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.93, Lovesac adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/LOVE/earnings">To track all earnings releases for Lovesac visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LOVE

Earnings Preview: Lovesac

Macro Economic Events

Econ #s

Economics

USA Wholesale Trade Sales (MoM) For February 2.4% Vs -0.9% Prior

<ul>
<li>Oracle confirmed a second massive data breach</li>
<li>The hacker gained access to sensitive information, including usernames, passwords, and encrypted passwords</li>
<li>The FBI and cybersecurity firm CrowdStrike Holdings are investigating</li>
</ul>
Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) has told customers a hacker has broken into its computer system and stolen client log-in credentials, <a href="https://www.reuters.com/technology/cybersecurity/oracle-tells-clients-second-recent-hack-log-in-data-stolen-bloomberg-news-2025-04-02/">Reuters</a> reported recently. The incident marks the second cybersecurity breach the company has come forward about in the last month.&nbsp;
According to insiders with knowledge of the situation, Reuters said that usernames, passwords, and encrypted passwords have been compromised. The company has said that the information was in an older system that has not been used for eight years, and therefore poses little risk to customers. However, the insiders were quoted saying that the data that was stolen included log-in credentials from as recent as 2024.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
</ul>
Oracle told customers that this data breach is separate from the <a href="https://www.benzinga.com/25/03/44549959/oracle-health-data-breach-exposes-patient-information-at-us-hospitals">health data breach</a> that was confirmed at the end of March. In that incident, a hacker accessed Oracle's servers and transferred data, including patient records, to a remote location. At the time, the company was heavily criticized for its lack of transparency because it did not alert affected parties for several weeks.
In the most recent incident, the unidentified hacker attempted to sell the stolen data online and sought an extortion payment from the company. Oracle initially denied that the breach had occurred. <a href="https://www.bloomberg.com/news/articles/2025-04-02/oracle-tells-clients-of-second-recent-hack-log-in-data-stolen">Bloomberg</a> reported that a statement was sent to customers that said no Oracle Cloud customers experienced a breach or lost any data.
Trending: <a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">With Shares Starting at Just $1.52, This Could be Your Chance to Invest in the Future of Healthcare.</a>
But researchers from private security company Trustwave Holdings reportedly validated the data, confirming that it was pulled from Oracle's systems. Karl Sigler, a senior security research manager at Trustwave, described it to Singapore's <a href="https://www.businesstimes.com.sg/companies-markets/telcos-media-tech/oracle-tells-clients-second-recent-hack-log-data-stolen">Business Times</a> as a "rich dataset" that could be used for phishing e-mails and account takeovers.&nbsp;
<a href="https://www.reuters.com/technology/cybersecurity/oracle-tells-clients-second-recent-hack-log-in-data-stolen-bloomberg-news-2025-04-02/">Reuters</a> also said that the FBI and cybersecurity firm CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) have been investigating the accusations.
The FBI and CrowdStrike reportedly declined Reuters&#8217; requests for comment on the incident. While Oracle has yet to release a public statement, it has acknowledged the hacking internally, sources reportedly told Reuters.
Read Next:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li><a href="https://www.benzinga.com/money/startengine-own">The $1.3 billion startup investment boom: How this company's explosive growth is opening doors for everyday investors with a new $500 minimum</a></li>
</ul>

CRWD

ORCL

Oracle Confirms Another Massive Data Breach, Customer Log-In Credentials Sold On Black Market

Analysts' ratings for Six Flags Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $49.33, a high estimate of $55.00, and a low estimate of $41.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 10.31%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744207238_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Six Flags Entertainment's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Arpine Kocharyan &#x7C;UBS &#x7C;Announces &#x7C;Buy &#x7C; $49.00&#x7C;- &#x7C; 
&#x7C;Michael Swartz &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $52.00&#x7C;$56.00 &#x7C; 
&#x7C;Ben Chaiken &#x7C;Mizuho &#x7C;Lowers &#x7C;Outperform &#x7C; $49.00&#x7C;$54.00 &#x7C; 
&#x7C;Brandt Montour &#x7C;Barclays &#x7C;Announces &#x7C;Overweight &#x7C; $41.00&#x7C;- &#x7C; 
&#x7C;Paul Golding &#x7C;Macquarie &#x7C;Maintains &#x7C;Outperform &#x7C; $55.00&#x7C;$55.00 &#x7C; 
&#x7C;Curry Baker &#x7C;Guggenheim &#x7C;Lowers &#x7C;Buy &#x7C; $50.00&#x7C;$55.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Six Flags Entertainment. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Six Flags Entertainment compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Six Flags Entertainment's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FUN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Six Flags Entertainment analyst ratings.</a>
<h2>All You Need to Know About Six Flags Entertainment</h2>
Six Flags Entertainment Corp is North America's regional amusement resort operator with approximately 27 amusement parks, around 15 separately gated water parks, and nine resort properties across the U.S., Canada, and Mexico. It provides coasters, themed rides, thrilling water parks, resorts, and a portfolio of beloved intellectual properties such as Looney Tunes, DC Comics, and PEANUTS.
<h3>Unraveling the Financial Story of Six Flags Entertainment</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3M period, Six Flags Entertainment showcased positive performance, achieving a revenue growth rate of 85.2% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Six Flags Entertainment's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -38.44% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Six Flags Entertainment's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -12.06%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Six Flags Entertainment's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -2.86%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 2.53.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Six Flags Entertainment: Insights From 6 Analyst Reviews

CarMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) is preparing to release its quarterly earnings on Thursday, 2025-04-10. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect CarMax to report an earnings per share (EPS) of $0.66.
CarMax bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.20, leading to a 0.05% increase in the share price on the subsequent day.
Here's a look at CarMax's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.61</td>
<td>0.86</td>
<td>0.94</td>
<td>0.49</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.81</td>
<td>0.85</td>
<td>0.97</td>
<td>0.32</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>-1.0%</td>
<td>0.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1744207239_0.png" alt="eps graph" />
<h3>Market Performance of CarMax's Stock</h3>
Shares of CarMax were trading at $73.31 as of April 08. Over the last 52-week period, shares are up 2.82%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analyst Insights on CarMax</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on CarMax.
The consensus rating for CarMax is Outperform, derived from 4 analyst ratings. An average one-year price target of $92.75 implies a potential 26.52% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Penske Automotive Group, Murphy USA and Lithia Motors, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Underperform trajectory for Penske Automotive Group, with an average 1-year price target of $156.67, suggesting a potential 113.71% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Murphy USA, with an average 1-year price target of $552.0, suggesting a potential 652.97% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Lithia Motors, with an average 1-year price target of $394.71, suggesting a potential 438.41% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary presents essential metrics for Penske Automotive Group, Murphy USA and Lithia Motors, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>CarMax</td>
<td>Outperform</td>
<td>1.22%</td>
<td>$677.65M</td>
<td>2.02%</td>
</tr>
<tr>
<td>Penske Automotive Group</td>
<td>Underperform</td>
<td>6.16%</td>
<td>$1.26B</td>
<td>4.54%</td>
</tr>
<tr>
<td>Murphy USA</td>
<td>Neutral</td>
<td>-7.07%</td>
<td>$599M</td>
<td>17.06%</td>
</tr>
<tr>
<td>Lithia Motors</td>
<td>Outperform</td>
<td>19.54%</td>
<td>$1.37B</td>
<td>3.26%</td>
</tr>
</tbody>
</table>

Key Takeaway:
CarMax ranks first in revenue growth among its peers. It has the highest gross profit margin. CarMax has the lowest return on equity compared to its peers.
<h3>Delving into CarMax's Background</h3>
CarMax sells, finances, and services used and new cars through a chain of around 250 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue (79% in fiscal 2024 due to the chip shortage) and wholesale about 13% (19% in fiscal 2024), with the remaining portion composed of extended service plans and repair. In fiscal 2024, the company retailed and wholesaled 765,572, and 546,331 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the US but still estimates that it had only about 3.7% US market share of vehicles 0-10 years old in 2023. It seeks over 5% share a few years from now. CarMax is based in Richmond, Virginia.
<h3>CarMax: Delving into Financials</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining CarMax's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.22% as of 30 November, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: CarMax's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 2.02%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): CarMax's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.02% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): CarMax's ROA stands out, surpassing industry averages. With an impressive ROA of 0.46%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: CarMax's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 3.09.
<a href="https://www.benzinga.com/quote/KMX/earnings">To track all earnings releases for CarMax visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What's Next: CarMax's Earnings Preview

Altria Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) short percent of float has risen 10.71% since its last report. The company recently reported that it has 41.93 million shares sold short, which is 2.48% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.79 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Altria Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744207229_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Altria Group has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Altria Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Altria Group's peer group average for short interest as a percentage of float is 2.73%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About Altria Group?

USA Wholesale Inventories (MoM) For February 0.3% Vs 0.3% Est.; 0.8% Prior

9 analysts have shared their evaluations of CubeSmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBE#NYSE">CUBE</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $46.11, along with a high estimate of $50.00 and a low estimate of $39.00. This current average has decreased by 9.07% from the previous average price target of $50.71. 
<img src="https://www.benzinga.com/files/images/story/2025/1744207225_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of CubeSmart by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ravi Vaidya &#x7C;Mizuho &#x7C;Announces &#x7C;Neutral &#x7C; $39.00&#x7C;- &#x7C; 
&#x7C;Brendan Lynch &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $49.00&#x7C;$50.00 &#x7C; 
&#x7C;Todd Thomas &#x7C;Keybanc &#x7C;Announces &#x7C;Overweight &#x7C; $47.00&#x7C;- &#x7C; 
&#x7C;Daniel Tricarico &#x7C;Scotiabank &#x7C;Lowers &#x7C;Sector Perform &#x7C; $46.00&#x7C;$52.00 &#x7C; 
&#x7C;Brad Heffern &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $48.00&#x7C;$53.00 &#x7C; 
&#x7C;Eric Luebchow &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $44.00&#x7C;$50.00 &#x7C; 
&#x7C;Ki Bin Kim &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $47.00&#x7C;$50.00 &#x7C; 
&#x7C;Brendan Lynch &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $50.00&#x7C;$54.00 &#x7C; 
&#x7C;Omotayo Okusanya &#x7C;Deutsche Bank &#x7C;Lowers &#x7C;Hold &#x7C; $45.00&#x7C;$46.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CubeSmart. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of CubeSmart compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of CubeSmart's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into CubeSmart's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CUBE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CubeSmart analyst ratings.</a>
<h2>All You Need to Know About CubeSmart</h2>
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Majority of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. The company derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
<h3>Financial Milestones: CubeSmart's Journey</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: CubeSmart's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 0.98%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: CubeSmart's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 38.06% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): CubeSmart's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.6%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): CubeSmart's ROA stands out, surpassing industry averages. With an impressive ROA of 1.62%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 1.06, CubeSmart adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CUBE

A Glimpse Into The Expert Outlook On CubeSmart Through 9 Analysts

In the current session, Cognizant Tech Solns Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>) is trading at $65.90, after a 0.86% decrease. Over the past month, the stock decreased by 16.64%, and in the past year, by 6.09%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1744207225_0_0.png" alt="Past Year Chart" />

<h3>Cognizant Tech Solns P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Cognizant Tech Solns has a lower P/E than the aggregate P/E of 88.05 of the IT Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744207225_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

CTSH

Price Over Earnings Overview: Cognizant Tech Solns

Press Releases

Central Puerto 1Q24 Earnings Release

Agreement with CAMMESA

Central Puerto Announces Reporting Date for the Second Quarter 2024 Financial Results Conference Call and Webcast

Central Puerto 2Q24 Earnings Release

Central Puerto Announces Reporting Date for the Third Quarter 2024 Financial Results Conference Call and Webcast

Central Puerto Is Advancing in Its Diversification Strategy and Positioning Itself as a Relevant Player in the Lithium Mining Industry

Central Puerto and YPF Luz Sign a Strategic Agreement to Develop an Electric Power Transmission Line Project and Boost the Growth of Mining in the Northern Argentina Region

With a New Investment, Central Puerto Becomes the Largest Shareholder of AbraSilver, Owner of the Diablillos Gold and Silver Project and Strengthens Its Presence in Mining.

Comments

Central Puerto

Noticias

Últimas noticias sobre Central Puerto (NYSE:CEPU) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL